[ad_1]
February 5th: China’s Sinovac Biotech said on Friday that late-stage trial data of its COVID-19 vaccine from Brazil and Turkey showed that it prevented hospitalization and death in COVID-19 patients, but had a much lower efficacy rate for block infections.
The trial of 12,396 people found that the CoronaVac vaccine was 100% effective in preventing COVID-19 patients from being hospitalized or dying and 83.7% effective in preventing cases requiring medical treatment, but only 50.65% effective in preventing people from being spread, according to a statement.
The trials evaluated the efficacy of the two-injection candidate vaccine 14 days after inoculation of participants, including healthcare workers treating COVID-19 patients.
In Turkey, the vaccine was tested in two stages among healthcare workers and the general population, and was found to have a 91.25% efficacy rate in preventing COVID-19 based on an analysis of 29 cases, the company said.
In early January this year, Brazilian researchers reported interim trial results of the CoronaVac vaccine showing that it was 50.4% effective in preventing symptomatic infections.
The efficacy rates of other vaccines have varied widely by country, an emerging pattern that reflects the impact of new variants.
Among the coronavirus variants currently of most concern to scientists and public health experts are British, South African and Brazilian variants, which appear to be spreading faster than others.
By comparison, the two COVID-19 vaccines currently licensed from Pfizer Inc and its partners BioNTech SE and Moderna Inc were shown to be approximately 95% effective at preventing disease in their late-stage pivotal trials. Those studies were done in the United States before extensive reports of variants.
Brazil’s national immunization program is currently based on CoronaVac and the vaccine developed by the University of Oxford and AstraZeneca Plc. Both have been approved for emergency use. – Reuters
[ad_2]
